

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/BEA0AFDB537EN.html>

Date: April 2020

Pages: 403

Price: US\$ 2,000.00 (Single User License)

ID: BEA0AFDB537EN

Abstracts

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2020, provides an overview of the Basal Cell Carcinoma (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under

Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 14, 8, 7 and 1 respectively.

Basal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Basal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment

Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics
Development

Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products

Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by 4SC AG, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Amgen Inc, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bayer AG, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Ltd, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bristol-Myers Squibb Co, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science Inc, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Galderma SA, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genentech Inc, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Invion Ltd, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by IO Biotech ApS, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma SL, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Leo Pharma AS, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Mayne Pharma Group Ltd, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Medivir AB, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co Inc, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by NuCana Plc, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by PellePharm Inc, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Phosplatin Therapeutics LLC, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by QBiotics Ltd, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Replimune Ltd, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Senhwa Biosciences Inc, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Sichuan Sinovation Biotechnology Co Ltd, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Singh Biotechnology LLC, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2020 (Contd..1), H1 2020

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

4SC AG
Adgero Biopharmaceuticals Holdings Inc
Amgen Inc
Bayer AG
Biofrontera AG
Biosceptre International Ltd
Bristol-Myers Squibb Co
Cannabis Science Inc
Galderma SA
Genentech Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Invion Ltd
IO Biotech ApS
Laboratories Ojer Pharma SL
Leo Pharma AS
Mayne Pharma Group Ltd
MediGene AG
Medivir AB
Merck & Co Inc
NuCana Plc
Ono Pharmaceutical Co Ltd

PellePharm Inc
Phosplatin Therapeutics LLC
QBiotics Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Senhwa Biosciences Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Sichuan Sinovation Bio-technology Co Ltd
Singh Biotechnology LLC
Transgene SA

I would like to order

Product name: Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/BEA0AFDB537EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BEA0AFDB537EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970